Endocrine Testing Market Report 2026

The endocrine testing market size has grown strongly in recent years. It will grow from $2.79 billion in 2025 to $3.05 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to diabetes prevalence, thyroid disorder incidence, clinical laboratory expansion, hormone testing awareness, chronic disease diagnostics growth.

The endocrine testing market size is expected to see strong growth in the next few years. It will grow to $4.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to preventive healthcare focus, personalized treatment planning, automation in hormone testing, expansion of diagnostic centers, endocrine disease screening programs. Major trends in the forecast period include growing prevalence of hormonal disorders, increased adoption of comprehensive hormone panels, expansion of preventive endocrine screening, rising demand for accurate diagnostic results, integration of advanced diagnostic technologies.

The increasing prevalence of diabetes is expected to support the growth of the endocrine testing market in the coming years. Diabetes encompasses a group of metabolic disorders characterized by elevated blood glucose levels. The rise in diabetes cases is driven by factors such as poor dietary habits, sedentary lifestyles, genetic susceptibility, and an expanding aging population. Endocrine testing, including hemoglobin A1c, fasting plasma glucose, and C-peptide tests, plays a critical role in diabetes care by enabling diagnosis, monitoring blood glucose levels, and evaluating insulin production and sensitivity. For example, in June 2024, the National Health Service (NHS), a UK-based government department, reported a substantial increase in diabetes diagnoses among individuals under 40 years of age, rising from 173,166 in 2022 to 216,440 in 2023. This marked growth underscores a concerning trend of rapidly increasing diabetes prevalence within younger populations. Consequently, the growing burden of diabetes is driving demand in the endocrine testing market.

Key players in the endocrine testing market are focusing on the development of point-of-care testing solutions to improve the accessibility and efficiency of diagnosing endocrine-related conditions. Point-of-care testing enables rapid result delivery, which supports timely diagnosis and management of conditions such as heart failure in patients presenting with symptoms including shortness of breath and fatigue. For instance, in April 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced a point-of-care NT-proBNP test in India, specifically designed to screen diabetes patients at risk of cardiovascular diseases, including heart failure (HF). This test supports early detection and intervention by helping clinicians identify high-risk type 2 diabetes (T2D) patients and initiate timely treatment discussions, ultimately contributing to improved clinical outcomes and patient well-being.

In February 2025, Hims & Hers Health Inc., a US-based healthcare technology company, acquired Trybe, Inc. for an undisclosed amount. Through this acquisition, Hims & Hers sought to expand its at-home diagnostic testing portfolio, enhance its hormone and wellness testing services, and strengthen its subscription-based customer experience. Trybe, Inc. is a US-based healthcare technology company specializing in at-home laboratory testing services, including whole-body and hormone-related tests, designed to support personalized health and wellness insights.

Major companies operating in the endocrine testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Roche Holding, Siemens Healthineers, Quest Diagnostics, Agilent Technologies Inc., PerkinElmer Inc., BioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., SD Biosensor Inc., Qiagen N.V., Ortho Clinical Diagnostics, Kronus Inc., Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Inova Diagnostics Inc., Sekisui Diagnostics LLC, Mercodia AB, ZEUS Scientific Inc., IBL International, Monobind Inc., Agilus Diagnostics, Tosoh Bioscience Inc., DiaSorin S.p.A.

North America was the largest region in the endocrine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endocrine testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the endocrine testing market by increasing costs of imported diagnostic instruments, reagents, and assay technologies. Hospitals and clinical laboratories in developed regions are most affected due to reliance on imported diagnostic supplies. These tariffs increase testing costs by raising equipment acquisition and per-test expenses, affecting access to hormonal diagnostics. However, they promote local manufacturing of diagnostic equipment, supporting regional self-sufficiency in endocrine testing.

The endocrine testing market research report is one of a series of new reports that provides endocrine testing market statistics, including endocrine testing industry global market size, regional shares, competitors with a endocrine testing market share, detailed endocrine testing market segments, market trends and opportunities, and any further data you may need to thrive in the endocrine testing industry. This endocrine testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Endocrine testing is a diagnostic approach used to measure hormone levels in the body, commonly through blood, urine, or saliva samples, to evaluate the functioning of the endocrine system. These tests play a vital role in identifying a wide range of endocrine disorders, such as diabetes, thyroid conditions, adrenal insufficiency, and pituitary gland abnormalities. Endocrine testing enables healthcare professionals to establish appropriate treatment and disease management strategies for affected patients.

The primary types of endocrine testing include estradiol (E2) test, follicle-stimulating hormone (FSH) test, human chorionic gonadotropin (HCG) hormone test, luteinizing hormone (LH) test, dehydroepiandrosterone sulfate (DHEAS) test, progesterone test, testosterone test, thyroid-stimulating hormone (TSH) test, prolactin test, and others. The estradiol (E2) test is a blood-based assay that determines estradiol levels in the body. These tests utilize a range of technologies, including tandem mass spectrometry, immunoassay, monoclonal and polyclonal antibody-based methods, sensor technology, clinical chemistry, and others, and are used by hospitals, clinical laboratories, diagnostic centers, and other healthcare facilities.

The endocrine testing market consists of revenues earned by entities by providing services such as hormone level testing, thyroid function testing, diabetes testing, adrenal function testing, reproductive hormone testing, pituitary function testing, and bone metabolism testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The endocrine testing market also includes sales of assay kits, analyzers, point-of-care testing devices, reagents, software solutions, quality control materials, and calibrators and controls. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.